Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNAPSE intranasal esketamine study in treatment-resistant depression
2013-004005-11Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Intranasal esketamine with Placebo nasal solution (2 arms). Primary endpoint: Change from baseline to 1 week endpoint in MADRS total score. Started Nov 2013; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2013-004005-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004005-11.